FDA Approval, FDA Application, Positive Safety Results, and Presentations - Research Report on Cubist, GSK, Rockwell Medical,

 FDA Approval, FDA Application, Positive Safety Results, and Presentations -
   Research Report on Cubist, GSK, Rockwell Medical, Arrowhead, and Horizon
                                    Pharma

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, October 24, 2013

NEW YORK, October 24, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Cubist
Pharmaceuticals Inc. (NASDAQ: CBST), GlaxoSmithKline plc (NYSE: GSK), Rockwell
Medical, Inc. (NASDAQ: RMTI), Arrowhead Research Corp. (NASDAQ: ARWR), and
Horizon Pharma, Inc. (NASDAQ: HZNP). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Cubist Pharmaceuticals Inc. Research Report

On October 21, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced that the
US Food and Drug Administration (FDA) approved its supplemental new drug
application (sNDA) for ENTEREG (alvimopan). According to Cubist, the sNDA
approval expands the indication for the use of ENTEREG to accelerate the time
to upper and lower gastrointestinal (GI) recovery following surgeries that
include partial bowel resection with primary anastomosis (i.e., re-connection
of the bowel following removal of the resected segment). Steven Gilman, Ph.D.,
Executive Vice President of Research and Development and Chief Scientific
Officer of Cubist, stated, "Delayed GI recovery is one of the most common
causes of prolonged hospital stays in patients undergoing major abdominopelvic
surgery. We are pleased that doctors will have the option to help speed GI
recovery for appropriate patients who have undergone surgeries that included a
bowel resection." The Full Research Report on Cubist Pharmaceuticals Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/92f2_CBST]

--

GlaxoSmithKline plc Research Report

On October 18, 2013, GlaxoSmithKline plc (GSK) announced that it has submitted
a supplemental Biologics License Application (sBLA) to the US Food and Drug
Administration (FDA) for the use of Arzerra (ofatumumab) in combination with
an alkylator-based therapy, to be used for treatment of Chronic Lymphocytic
Leukaemia (CLL) patients who have not received prior treatment and are
inappropriate for fludarabine-based therapy. GSK further reported that the
application is based primarily on results from an international, multi-centre,
randomised Phase III study of ofatumumab in combination with chlorambucil
versus chlorambucil alone in more than 400 patients with previously untreated
CLL. The Full Research Report on GlaxoSmithKline plc - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/2a35_GSK]

--

Rockwell Medical, Inc. Research Report

On October 21, 2013, Rockwell Medical, Inc. (Rockwell Medical) announced
positive safety results of its large Phase 3 short-term safety study that was
conducted in support of the New Drug Application for marketing approval of
Triferic. Rockwell Medical reported that Triferic is its late-stage
investigational iron-replacement drug for the treatment of iron deficiency in
chronic kidney disease patients receiving hemodialysis. Rob Chioini, Founder,
Chairman and CEO of Rockwell Medical commented, "We are very pleased with the
results of the short-term safety study." Chioini added, "Triferic's clean
safety profile together with its unique mode of action enabling efficient iron
delivery and hemoglobin maintenance, while significantly reducing the need for
ESA, highlight its potential to be the market-leading iron therapy treatment
for CKD-HD patients." The Full Research Report on Rockwell Medical, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/3079_RMTI]

--

Arrowhead Research Corp. Research Report

On October 18, 2013, Arrowhead Research Corp. (Arrowhead) announced its
presentation of data on ARC-520, its hepatitis B drug candidate, at two
upcoming scientific conferences. Arrowhead reported that Robert E. Lanford,
Ph.D., Texas Biomedical Research Institute, will be presenting on November 3,
2013, at the AASLD - The Liver Meeting in Washington scheduled to be held on
November 1, 2013 to November 5, 2013. The Company noted that Lanford's
presentation is entitled "ARC-520 RNAi therapeutic reduces HBV DNA, S and e
antigen in a chimpanzee." The Full Research Report on Arrowhead Research Corp.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/0c95_ARWR]

--

Horizon Pharma, Inc. Research Report

On October 21, 2013, Horizon Pharma, Inc. (Horizon Pharma) announced that two
published abstracts of its approved treatment RAYOS (prednisone)
delayed-release tablets will be presented during the American College of
Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP)
Annual Scientific Meeting, to be held from October 25, 2013 to October 30,
2013 in San Diego, CA. According to the Company, presentation 2255, based on
the abstract - Threshold Analysis of Patient Reported Morning Stiffness Where
Delayed-Release (DR) Prednisone Was Compared to, and Replaced, Immediate
Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving
Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) Over 1 Year, as
well as presentation 2265, based on the abstract - Switching From Immediate
Release (IR) Prednisone to Delayed Release (DR) Prednisone Improves Patient
Reported Outcomes In Rheumatoid Arthritis (RA) Patients On Conventional
Disease-Modifying Antirheumatic Drugs (DMARDs), both will be held
simultaneously on Tuesday, October 29, 2013, at 8:30 a.m. to 4:00 p.m. The
Full Research Report on Horizon Pharma, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/05ea_HZNP]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.